Publication Type : Conference Proceedings
Publisher : ESMO
Source : In ESMO 2021. Annals of Oncology. 2021 Sep 1;32:S471.
Url : https://www.annalsofoncology.org/article/S0923-7534(21)02768-X/fulltext
Campus : Kochi
School : School of Medicine
Year : 2021
Abstract : Background PI3K mutations contribute to endocrine resistance. PIK3CA mutation may be present de novo at the time of diagnosis or may be acquired later. The present study evaluated the incidence and distribution of de novo PIK3CA mutations in hormone receptor-positive / HER2-negative metastatic breast cancer (MBC) and its impact on clinical outcomes of patients treated with CDK4/6 inhibitors.
Cite this Research Publication : Pavithran K, Jayamohanan H, Jose WM, Soman S, Vijaykumar DK, Ariyannur PS. "256P PI3K mutation is associated with reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer". In ESMO 2021. Annals of Oncology. 2021 Sep 1;32:S471.